( MENAFN - EQS Group) Everest Medicines (HKEX 1952, "Everest" , or the "Company”)'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, nasdaq Stockholm: CALTX) (“Calliditas”), has announced an additional efficacy analysis of NEFECON® in IgA nephropathy (IgAN) at the 61st European Renal Association congress (ERA 2024) . The presented efficacy analysis of NEFECON® and sparsentan showed that treatment with NEFECON® 16 mg/day for 9 months was associated with estimated glomerular filtration rate (eGFR) benefit compared with continuous treatment with sparsentan 400 mg/day over 2 years [1]. “The positive results presented at the ERA 2024 strongly demonstrate that NEFECON® can bring stronger benefits to IgAN patients in protecting kidney function.
With approximately 5 million IgAN patients in China and over 100,000 newly diagnosed patients annually, there is a significant unmet clinical demand,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.“Most Chinese patients are at risk of progression to end-stage-renal-disease within their lifespan, as patients show more aggressive disease progression. Therefore, proactive treatment is needed to intervene and control such risk, delaying the need for dialysis or kidney transplantation.
As the world's first-in-disease therapy for IgAN, NEFECON® has been officially commercialized in mainland China. In the future, we will continue to improve the accessibility of NEFECON® and bring this innovative .
